Disparities in Kidney Disease: The Need for Targeted Programmes and Interventions to Promote Health Equity across the Globe
Disparities in Kidney Disease
DOI:
https://doi.org/10.53778/pjkd73257Keywords:
Disparities, Diversity, Equity, Inclusion, Kidney DiseaseAbstract
Kidney disease is a major public health issue that affects over 850 million people globally. The burden of kidney disease varies greatly around the world, as do its identification and treatment. The causes of these disparities are multifactorial, including socioeconomic status, race and ethnicity, sex/gender, age, geographic location, language and cultural barriers, healthcare system and provider factors, and social determinants of health, among others. In this paper, poor health outcomes associated with disparities in kidney disease, strategies to mitigate these disparities, and the importance of diversity, equity, and inclusion (DEI) in kidney disease are highlighted, while targeted programmes, and interventions rooted in DEI tenets are recommended.
References
Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019;96:1048-50.
Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 1982;306:1276-9.
Crews DC, Liu Y, Boulware LE. Disparities in the burden, outcomes, and care of chronic kidney disease. Curr Opin Nephrol Hypertens 2014;23:298–305.
Tsai JW, Cerdena JP, Goedel WC, Asch WS, Grubbs V, Mendu ML. Evaluating the impact and rationale of race-specific estimations of kidney function: Estimations from US NHANES 2015-2018. E Clinical Medicine 2021;42:101197.doi: 10.1016/j.eclinm.2021.101197.
National Kidney Foundation (NKF). Health disparities: 2024. Available from: https://www.kidney.org/advocacy/legislative-priorities/health-disparities. [Last accessed on 2024 May 05]
Kevin Tucker J. Social justice as a tool to eliminate inequities in kidney disease. Semin Nephrol 2021;41:203-10.
Centers for Disease Control and Prevention. Diabetes Report Card. 2019 CDC , Atlanta ,USA: US Dept of Health and Human Services. Available from: https://www.cdc.gov/diabetes/library/reports/ reportcard.html. [Last accessed on 2023 Nov 11].
Ulasi II, Tzur S, Wasser WG, et al. High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria. Nephron Clin Pract 2013;123:123-8.
Limou S, Nelson GW, Kopp JB, Winkler CA. APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis 2014;21:426-33
Melk A, Babitsch B, Borchert-Mörlins B, Claas F, Dipchand AI, Eifert S, et al. Equally interchangeable? how sex and gender affect transplantation. Transplantation 2019;103:1094-110.
Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 2015;88:950-7.
Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Global Health 2016;4:e307-19.
Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018;392:2052–90.
Stanifer JW, Von Isenburg M, Chertow GM, Anand S. Chronic kidney disease care models in low- and middle-income countries: a systematic review. BMJ Glob Health 2018;3. doi: 10.1136/bmjgh-2018-000728.
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020;395:709-33.
Bello A, Okpechi I, Levin A, Ye F, Saad S, Zaidi D, et al. ISN–Global Kidney Health Atlas: A report by the International Society of Nephrology: An Assessment of Global Kidney Health Care Status focussing on Capacity, Availability, Accessibility, Affordability and Outcomes of Kidney Disease. International Society of Nephrology, Brussels, Belgium. 2023 Available from: https://www.theisn.org/wp-content/uploads/media/ISN%20Atlas_2023%20Digital.pdf. [Last accessed 2024 May 08].
Bello AK, Levin A, Tonelli M, Okpechi IG, Feehally J, Harris D, et al. Global Kidney Health Atlas: A report by the International Society of Nephrology on the current state of organization and structures for kidney care across the globe. International Society of Nephrology, Brussels, Belgium. 2017. Available from: https://www.theisn.org/wp-content/uploads/2021/05/GKDAtlas_2017_FinalVersion-1.pdf. [Last accessed 2024 May 08].
Redmon JH, Elledge MF, Womack DS, Wickremashinghe R, Wanigasuriya KP, Peiris-John RJ, et al. Additional perspectives on chronic kidney disease of unknown aetiology (CKDu) in Sri Lanka—lessons learned from the WHO CKDu population prevalence study. BMC Nephrol. 2014;15:125. doi: 10.1186/1471-2369-15-125.
Ganguli A. Uddanam nephropathy/regional nephropathy in India: preliminary findings and a plea for further research. Am J Kidney Dis 2016;68:344–8.
Almaguer M, Herrera R, Orantes CM. Chronic kidney disease of unknown etiology in agricultural communities. MEDICC Rev. 2014;16:9–15.
Ramírez-Rubio O, Amador JJ, Kaufman JS, Weiner DE, Parikh CR, Khan U, et al. Urine biomarkers of kidney injury among adolescents in Nicaragua, a region affected by an epidemic of chronic kidney disease of unknown aetiology. Nephrol Dial Transplant 2015;31:424–32.
Barker DJ, Osmond C, Kajantie E, Eriksson JG. Growth and chronic disease: findings in the Helsinki Birth Cohort. Ann Hum Biol 2009;36:445–58.
Stanifer JW, Lunyera J, Boyd D, Karia F, Maro V, Omolo J, et al. Traditional medicine practices among community members with chronic kidney disease in northern Tanzania: an ethnomedical survey. BMC Nephrol 2015;16:170. doi: 10.1186/s12882-015-0161-y.
Johnston A, Holt DW. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol 2014;78:218–43.
Mackey TK, Liang BA, York P, Kubic T. Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment. Am J Trop Med Hyg 2015;92:59–67.
McDowell A, The importance of diversity in kidney disease trials: A Q&A with the American Kidney Fund. Available from: https://www.antidote.me/blog/diversity-in-kidney-disease-trials.[Last accessed 2023 Nov 23].
Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015 16;385:1975-82.
Agarwal A. Nephrology- Taking the Lead. Clin J Am Soc Nephrol 2021;16:1113-6.
Crews DC, Collins CA, Cooper LA. Distinguishing workforce diversity from health equity efforts in medicine. JAMA Health Forum 2021;2:e214820.doi: 10.1001/jamahealthforum.2021.4820
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Kidney Diseases

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.